4D Molecular Therapeutics, Inc.
FDMT
$11.17
$0.474.39%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -45.79% | -78.49% | -68.75% | -59.53% | -49.56% |
| Total Depreciation and Amortization | 15.46% | 16.35% | 15.75% | 16.63% | 14.40% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -1.08% | 2.11% | -3.08% | 2.01% | 8.13% |
| Change in Net Operating Assets | -106.12% | 809.19% | -294.50% | -14.76% | 1,354.85% |
| Cash from Operations | -61.85% | -95.40% | -99.10% | -77.57% | -54.55% |
| Capital Expenditure | 54.08% | -70.09% | -50.14% | -36.63% | -2.14% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 114.22% | 117.94% | 98.13% | -352.05% | -447.80% |
| Cash from Investing | 113.58% | 116.73% | 96.21% | -361.36% | -465.02% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -99.54% | -99.42% | -96.04% | 115.04% | 120.86% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -99.54% | -99.42% | -96.04% | 115.04% | 121.53% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -57.69% | -136.83% | -172.11% | -150.71% | -152.66% |